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Introduction
AngII is a key hormone involved in both cardiovascular 
homeostasis and development of multiple cardiac diseases.1 
In the heart, sustained AngII signalling promotes myocar-
dial hypertrophy and fibrosis through induction of several 
immediate early genes (c-fos, c-mys and c-jun), late genes 
including α-smooth muscle actin (αSMA), collagens and 
natriuretic peptides (ANP and BNP), and the growth fac-
tors angiotensinogen and transforming growth factor β 
(TGF-β).2,3 Eventually the hypertrophic and fibrotic 
response leads to heart failure. Hence, the AngII type 1 
receptor (AT1R) is a prominent drug target in cardiovascu-
lar medicine. The classical description of AT1R signalling 
depicts Gαq-protein activation and downstream signalling 
through the canonical MAP kinases Erk1/2 that translocate 
to the nucleus and initiate gene transcription.4–6 We previ-
ously demonstrated that AT1R signalling also regulates five 
microRNAs (miRNAs), including the miR-132/212 family, 
in primary cultures of cardiac fibroblasts.4
MiRNAs are endogenous short non-coding RNAs that 
interact with specific target mRNAs based on sequence 
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complementarities in the 3´UTR of the target mRNA, 
resulting in translational repression and/or mRNA degra-
dation.7,8 miR-132 and miR-212 are highly conserved 
miRNAs, closely clustered in the genome9 and are tran-
scribed together under the regulation of cAMP response 
element binding protein (CREB),10 known to be an AngII-
regulated gene. In most tissues, miR-132 is expressed at 
much higher levels than miR-212, which suggests that 
miR-132 may be the predominant regulator of the two.11 
MiRNA family members often have identical target speci-
ficity because they share common ‘seed regions’, the 2–8 
bases positioned at the 5´end of the miRNA representing 
the primary contributors to mRNAs target recognition. 
However, the interactions of the 3´end of the miRNAs are 
also important determinants of target specificity within 
miRNA families.7 Therefore miR-132 and miR-212 that 
belong to the same family may be functionally redundant 
in regulation of some target genes but not of others.11
Several pieces of data suggest that AngII dictates miR-
132 and miR-212 expression. We previously demonstrated 
that AngII increases miR-132 and miR-212 expression 
through an AT1R-Gαq-ERK1/2-dependent pathway4 in a 
cell line overexpressing AT1R and in primary cultures of 
cardiac fibroblasts. In line with these findings, we subse-
quently found that miR-132 and miR-212 increased in 
response to AngII in hypertensive rats while these miR-
NAs decrease in human patients treated with AngII recep-
tor blockers.12 Others have shown that the miR-132/212 
family promotes cardiac hypertrophy and autophagy in 
cardiomyocytes,13 and that miR-132/212 null mice are 
protected from pressure overload-induced heart failure.13 
However, several questions regarding the mechanisms and 
downstream regulation of miR-132 and miR-212 targets 
involved in AngII signalling still remain unanswered. We 
therefore undertook a detailed analysis of miR-132/212 
targets to understand the role of miR-132 and miR-212 in 
AngII signalling networks in cardiac fibroblasts.
Materials and methods
Cardiac fibroblast cell culture
Adult rat-derived fibroblasts were isolated by the principle 
of selective plating as previously described,14–16 with some 
modification. In brief, 8–10-week-old male Sprague-
Dawley rats (Taconic, Denmark) were sacrificed and 
hearts were rinsed in a preparation buffer (1.2 mM 
KH2PO4, 0.25 g/l Na2CO3, 6.44 g/l NaCL, 2.6 mM KCl, 
1.2 mM Mg2SO4, 11 mM glucose supplemented with 50 
IE/ml Heparin). Arterial tissue and visible vasculature 
were removed and ventricles were trypsinised twice for 10 
min in 10 ml 0.08% Trypsin (BD, New Jersey, USA) sup-
plemented with DNase (Sigma-Aldrich, St. Louis, USA). 
Tissue fragments were washed, minced and incubated with 
9500 U Collagenase Type 2 (Worthington Biochemical 
Corp., USA) in HBSS (Gibco, Life Technologies, USA) 
and supplemented with DNase, for 70 min disrupted by 
swirling. The suspension was dissociated by thorough 
pipetting in DMEM supplemented with 10% fetal bovine 
serum (FBS) and 50 U.ml-1 penicillin and 50 U.ml-1 strep-
tomycin (PS) (Gibco, Life Technologies, USA) before 
being passed across a 100 µm filter (DB, New Jersey, 
USA). Cells were incubated for 6 min on ice with 0.9% 
NH4Cl, 0.08% NaHCO3, 20 µM Tetrasodium EDTA for 
lysis of erythrocytes and washed before the suspension 
was pre-plated for 1 h in cell culture dishes in 
DMEM/10%FBS/1%PS. After 1 h, the cultures were 
washed thoroughly with PBS and the remaining adherent 
cells were cultivated for 3 days to sub-confluence (~80%) 
and used directly as specified in the text. Cells were 
deprived of serum for 1 h prior to stimulation with 100 nM 
AngII (Sigma-Aldricht, St. Louis, USA).
Cell number and volume
After 44 h, cultured cells were gently detached by 0.25% 
Trypsin-EDTA (Invitrogen, Life Technologies, USA). 
Cells were resuspended and diluted in isotonic fluid and 
counted in the range of 8–24 µm. The cell number and cell 
diameter were measured using a Beckman Coulter 
Multisizer Z2 (RAMCON A/S, Denmark) and counting 
was performed in three independent experiments, each 
comprising triplicate measurements.
MTT assay
After 44 h cell viability was validated by the mitochondrial 
activity through the reduction of MTT (3-(4,5.
Dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromid) by 
the cells, using standard Vybrant MTT proliferation assay 
(Invitrogen, Life Technologies, USA). In brief, cells were 
incubated at 37°C/5% CO2 with 0.5mg/ml MTT in phenol 
red-free cultivation medium for 4 h. Formazan crystals 
were solubilised in 10% SDS/0.01 M HCl at 80 rpm and 
absorbance was measured at 570–690 nm.
Immunohistochemistry
Cells were fixed for 10 min in 4% paraformaldehyde 
(PFA) in PBS (Bie and Berntsen LAB, Denmark), permea-
bilised for 10 min in 0.1% TX100 (Sigma-Aldrich, St. 
Louis, USA) and blocked for 15 min with 2% BSA 
(Calbiochem, USA) in TBS. Cells were incubated over-
night in 1% BSA/TBS with mouse anti-α-smooth muscle 
actin (αSMA; Sigma-Aldrich; clone 1A4, 11 µg/ml), visu-
alised by incubation for 1 h with Alexa 555-conjugated 
secondary antibody (Invitrogen, Life Technologies, USA: 
1:200). As isotype, control mouse anti-IgG2a (Sigma-
Aldrich; UPC-10) were applied. Slides were mounted with 
mounting medium (Vectorshield, Vector Lab, UK) 
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containing DAPI for staining of nuclei, and images were 
acquired using a Leica DMI4000B Cool Fluo Package 
instrument equipped with a Leica DFC340 FX Digital 
Camera. In all experiments, exposure (camera settings) 
and picture processing (brief adjustment of contrast/bright-
ness and colour balance by Photoshop CS5) were applied 
equally to all images
Transfection
Cardiac fibroblasts were equilibrated in serum-free 
medium 1 h and thereafter transfected for 4 h with 30 nM 
mature synthetic pre-miRNA (15 nM of each miRNA 
when used in combination), using Lipofectamine 2000 
protocol (Invitrogen, Life Technologies, USA) as recom-
mended by the manufacturer, except that DMEM was 
applied as transfection medium. Transfected cardiac fibro-
blasts were washed and further cultured for 24 h in serum-
free DMEM. Pre-miR-132 (PM10166), pre-miR-212 
(PM12534) and pre-miR scramble controls (AM17110) 
were purchased from Ambion, Life Technologies, USA.
mRNA and miRNA analysis
Relative qRT-PCR of mRNA and miRNA were performed 
as previously described.16,17 Briefly, total RNA was 
extracted using TriReagent protocol (Molecular Research 
Center, Inc. Cincinnati, USA), and RNA purity, integrity 
and quantity were examined by spectrophotometry 
(Nanodrop® Technologies, Thermo Scientific, USA) and 
Bioanalyzer (Agilent 2100) measurements. SYBR green-
based relative quantitative mRNA PCR was performed on 
reverse-transcribed cDNA (High Capacity cDNA RT kit; 
Applied Biosystems, Life Technologies, USA) using prim-
ers listed in Table S1. For TaqMan-based miRNA, qRT-
PCR primers specific for rat miR-132 (#000457), miR-212 
(#002551), miR-17 (#002308), miR-191 (#002299) were 
purchased from Applied Biosystems, Life Technologies, 
USA. Amplification and detection were performed using 
7900HT Fast Real-Time PCR System (Applied Biosystems, 
Life Technologies, USA). As recommended by others18,19 
and previously described,16,17 we used the qBase+ software 
to normalise all qRT-PCR data against multiple stably 
expressed control genes (Table S2).
mRNA microarray and data processing
Total RNA samples of 500 ng were reverse-transcribed 
followed by in vitro transcription into biotin-labelled 
cRNA using the MessageAmp II Enhancer kit (Applied 
Biosystems, Life Technologies, USA) according to the 
manufacturer’s instruction for a single-round amplifica-
tion. Purified and fragmented biotin-labelled cRNA was 
hybridised to Affymetrix® GeneChip (Rat Genome 230 2.0 
Array) and subsequently stained, washed and scanned 
using the GeneChip Fluidics station 450 and the GeneChip 
Scanner 3000 (Affymetrix, Santa Clara, CA, USA). Array 
quality was evaluated using affyQCReport package from 
Bioconductor including NUSE (Normalised Unscaled 
Standard Error) and RLE (Relative Log Expression) plots. 
Normalisation and background correction was performed 
with R software using the vsn package by Bioconductor 
resulting in data that were log2 transformed. The dataset 
was subjected to Sylamer analysis to identify the represen-
tation of 3´UTR miRNA binding sites in genes expressed 
under the influence of miR-132/212 overexpression. 
Sylamer is a bioinformatic program that catalogues puta-
tive miRNA binding sites in the 3´UTR regions of genes 
and determines if the pattern deviates from neutral expec-
tations in rank-ordered list of genes. Here, Sylamer is used 
to find significant depletion of a word that is complemen-
tary to the seed sequence of miR132/212, i.e. GACTGTT.
Genes identified by Sylamer analysis (~600) were sub-
sequently analysed by Ingenuity pathway analysis (http://
www.ingenuity.com) for potential targets involved in the 
renin–AngII signalling pathway.
Statistical analysis
All analyses comprised independent experiments, and 
one-way ANOVA or paired t-tests were performed as 
indicated (GraphPad Prism (5.0 version) software) to 
test significant levels. A value of p ≤ 0.05 was consid-
ered statistically significant. All error bars indicate mean 
± s.d. The primary rat-derived cardiac fibroblasts were 
not passaged and thus the number of experiments (n) 
reflects the number of cell batches treated as independ-
ent experiments.
Results
AngII regulated miRNAs in vitro
We previously established an efficient protocol for isola-
tion of primary rat-derived cardiac fibroblasts,4 allowing 
us to search for potential targets of the AngII-induced 
miRNAs (i.e. miR-132 and miR-212) identified in our pre-
vious study.4,12 The cardiac fibroblasts were incubated 
with 100 nM AngII resulting in deposition of αSMA stress 
components, increased cell size and cell viability (Figure 
1(a) and (b)). Furthermore using qRT-PCR, we confirmed 
that the expression of both miR-132 and miR-212 were 
significantly upregulated by two-fold in fibroblasts stimu-
lated with AngII as compared with controls (Figure 1(c)).
MiR-132/212 overexpression increase cardiac 
fibroblast size
To analyse whether miR-132/212 overexpression has an 
impact on cardiac fibroblasts in vitro and to search for 
potential miR-132/212 targets, we applied transfection of 
synthetic pre-miR-132 and pre-miR-212 individually 
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(Figure S1) or in combination (Figure 2(a)). MiR-132 was 
increased by ~44.500 fold, whereas miR-212 was increased 
by ~650 fold, compared with respective pre-miR-Controls. 
Interestingly, we found that overexpressing a combination 
of miR-132/212 led to a significant (p < 0.01) cell size 
enlargement, indicating that miR-132/212 mimics the 
effect of AngII on fibroblast cell volume (Figure 2(b)) 
compared with controls. No changes were observed for 
cell number or mitochondrial activity after transfection of 
the miRNAs (Figure 2(b)).
MiR-132 and miR-212 target a wide panel of 
mRNA genes
To identify miR-132/212 molecular functions in AngII 
signalling pathways, we overexpressed miR-132/212 
followed by a genome-wide approach identifying 
approximately 20,000 annotated genes, of which 2000 
genes were differentially expressed (p < 0.05). Next, 
potential miR-132/212 targets were detected using 
Sylamer software and Ingenuity pathway analysis. This 
process identified 24 candidate target genes for the 
miR-132/212, of which we validated 22 genes. A flow 
chart of the selection process is depicted in Figure 3(a). 
Briefly, the software program, Sylamer, identified pres-
ence of the complementary sequence to the miR-
132/212 seed region in the 33% most regulated mRNAs 
from the dataset (1665 downregulated and 4535 upregu-
lated, in total 6200) (Figure 3(b)). From this analysis, 
600 downregulated genes enriched for the miR-132/212 
binding site were selected and compared with predicted 
miR-132/212 targets from three different miRNA target 
prediction algorithms, i.e. TargetScan, miR-base and 
PicTar. Interestingly, 30 genes were identified as targets 
Table 1. Target validation.
Gene Array RT-qPCR
FC to control 
Mean ± sd; n = 6
p-value FC to control
Mean ± sd; n = 3
p-value
Ctrl 1.00 1.00
AC (ADCY6) 0.99 ± 0.01 *0.02 0.92 ± 0.04 0.09
AGTR1 0.99 ± 0.03 *0.04 0.99 ± 0.07 0.12
ANXA4 0.98 ± 0.01 *0.002 0.70 ± 0.01 0.11
BTG2 0.95 ± 0.004 *0.01 0.80 ± 0.20 0.19
CALU 0.98 ± 0.01 *0.01 0.74 ± 0.10 0.08
CDKN1A 0.98 ± 0.02 0.06 0.75 ± 0.19 0.10
cJUN 1.00 ± 0.05 0.18 0.90 ± 0.09 0.20
DYRK2 0.98 ± 0.03 0.21 0.66 ± 0.02 *0.04
EFEMP2 0.99 ± 0.01 0.07 0.83 ± 0.03 0.14
EGR1 0.98 ± 0.01 *0.008 0.72 ± 0.02 0.08
GRB2 0.99 ± 0.03 0.71 1.10 ± 0.04 *0.04
JAK2 0.98 ± 0.02 0.07 0.83 ± 0.11 0.14
Jarid1A 1.01 ± 0.07 0.14 0.92 ± 0.46 0.63
MAP3K3 (MEKK3) 0.99 ± 0.04 0.38 0.67 ± 0.09 *0.02
PKC genes:  
PRKCα 1.01 ± 0.03 0.29 0.86 ± 0.05 0.05
PRKCγ 1.01 ± 0.10 0.80 0.81 ± 0.09 0.10
PNN 0.97 ± 0.07 0.33 0.84 ± 0.16 0.35
PTEN 1.00 ± 0.02 0.67 1.15 ± 0.36 0.76
RASA1 0.99 ± 0.02 0.15 0.80 ± 0.05 0.06
NRAS 0.97 ± 0.03 0.11 0.77 ± 0.04 0.24
KRAS 0.98 ± 0.03 0.29 0.76 ± 0.15 0.15
SOD2 0.97 ± 0.02 *0.002 0.87 ± 0.03 0.24
VCAM 0.97 ± 0.01 *0.002 0.85 ± 0.05 0.40
ZFYVE16 (SARA) 1.00 ± 0.02 0.76 0.81 ± 0.02 0.23
RPL13A 1.01 ± 0.04  
GAPDH 0.99 ± 0.04  
Fold change of pre-miR-132/212 transfected cells to pre-miR-Control. 24 genes were selected from array, sylamer analysis, Ingenuity pathway analy-
sis and by comparison with prediction algorithms. One gene (PTEN) was added, due to previous publications. Of the 24 genes, 22 were validated as 
attenuated by miR-132/212, two genes were found to be upregulated (PTEN and GRB2). Two genes were identified as significantly downregulated 
(DYRK2 and MAP3K3). RPL13a and GAPDH were used as reference genes (for reference genes, M and CV values see Table S2).
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by Sylamer and in at least one of the target prediction 
algorithms (Table S3).
Ingenuity pathway analysis of the selected 600 genes 
enriched for the miR-132/212 binding site identified seven 
miR-132/212 targets in the renin–angiotensin–aldosterone 
system (RAAS) (Figure 4). In general, the Ingenuity-
generated dataset depicts a pattern in which more genes in 
the RAAS pathway are downregulated than upregulated 
(20/13, respectively) and several genes are identified as 
targets for miR-132 and miR-212 (orange circles). 
Furthermore, CREB is included in Figure 4, as this 
transcription factor is responsible for miR-132/212 tran-
scription and because CREB has previously been sug-
gested as a miR-132/212 target.20
MiR-132 and miR-212 fine-tune the AngII 
signalling pathway
Altogether 24 predicted miR-132/212 targets were selected 
for validation by qRT-PCR (Table 1) together with two 
previous published target genes, namely p120 RasGAP 
(also known as RASA1; already in our list) and phosphatase 
Figure 1. AngII effect on primary cultures of cardiac fibroblasts. A) Immunohistochemistry of primary rat-derived 
cardiac fibroblasts stimulated with 100 nM AngII for 44 h and stained for αSMA and DAPI. Pictures show representative sections 
in the cultures. B) Cell number and cell diameter (calculated as volume), were measured using a Bechman Coulter Counter. Cell 
viability was measured using MTT assay for mitochondrial activity. C) miRNA qPCR of AngII stimulated primary cultures of cardiac 
fibroblasts. Data are represented as mean ± sd. Statistical significance was tested by paired t-test, n = 3. *p < 0.05. Expression of 
miR-132 and miR212 was normalised to two stable reference genes (for reference genes, M and CV values see Table S2).
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Figure 2. MiR-132 and miR-212 impact on cardiac fibroblasts. A) miRNA quantification by qRT-PCR of cardiac fibroblasts 
transfected with a combination of miR-132 and miR-212 (pre-miR-132/212) and compared to scramble miRNA transfected cells 
(pre-miR-Control). miR-132 and miR-212 was normalised against two stable reference genes (for reference genes, M and CV values 
see Table S2). B) miR-132/212 effect on cell number, cell diameter (calculated as volume) and cell viability was measured using a 
Bechman Coulter Counter or by MTT assay analysing mitochondrial activity. For simplicity, this figure shows the pre-miR control 
and the combinatorial miR-132/212 treatment. For data on all treatments see Figure S1.
For both A) and B) data are represented as mean ± s.d. and statistical significance was tested by paired t-test, n = 3. **p < 0.01, *** p < 0.001.
Figure 3. Flow chart and Sylamer analysis. A) Flow chart of the process of finding targets for miR-132/212. B) Sylamer 
enrichment landscape plots for 3´ UTR binding sites for miRNAs. The top 33% of miR-132/212 regulated genes (from 
downregulated (1665 genes) to upregulated (4535 genes) from microarray is analysed. The x-axis represents the sorted gene list. 
The y-axis shows the hypergeometric significance for each word at each leading bin. Positive values indicate enrichment (-log10 
(p-value)) and negative values, depletion (log10(p-value)). Seed sequence for miR-132/212 is underlined. Grey lines show profiles of 
words unrelated to the seed region of miR-132/212, and coloured lines represent selected words. Red line is complementary to 
the miR-132/212 seed sequence. Blue line is complementary to the seed sequence but shifted 1 nt towards the 5´end of the seed 
sequence, disrupting perfect binding.
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and tensin homolog (PTEN). Interestingly, all target genes 
were found to be downregulated by overexpression of 
miR-132/212 (except GRB2 and PTEN). Out of 22 genes 
downregulated genes, two genes (DYRK2 and MAP3K3) 
were identified as significantly downregulated (p < 0.05) 
while many were borderline significant (0.05 < p < 0.2), 
confirming a strong tendency for these genes to be regu-
lated by miR-132/212 in the AngII signalling pathway 
Figure 4. Pathway analysis using Ingenuity software. 600 genes enriched for the nucleotide sequence complementary to 
the miR-132/212 seed sequence selected from Sylamer analysis were subjected to pathway analysis. A red-coloured gene describes 
upregulation and a green-coloured gene describes downregulation in the dataset. Genes coloured red/green are genes with more 
than one probe that show different regulation. Genes in white boxes are not present in the dataset. Genes with an orange circle 
depicts genes identified as targets for miR-132/212. Genes with a yellow circle (JAK2 and GRB2) are genes with no detectable 
miR-132/212 binding sequence, but predicted to be a miR-132/212 target by the Ingenuity pathway analysis. Ingenuity identified 
miR-132/212 targets in RAS; JAK2, RAS, GRB2, cJUN, PKC, AC and AGTR1. In addition, we included target genes selected from the 
microarray and compared with prediction algoritms: RASA1, CALU, MAP3K3, SOD2, along with the transcription factor CREB, which 
is known to transcribe miR-132 and miR-212. All potential targets were validated using qRT-PCR (Table 1).
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(Table 1). Keeping in mind that miRNAs typically exert 
modest inhibitory effects on many mRNAs, these results 
strongly support the notion that miR-132 and miR-212 
function as cellular conductors fine-tuning the AngII 
actions in cardiac fibroblasts.
Discussion
Given the emerging roles of the miR-132/212 family in 
cardiac hypertrophy and hypertension,12,13 it will be impor-
tant to characterise the molecular networks and targets by 
which these miRNAs exert their functions. We previously 
demonstrated that signalling through the AT1R and Gαq-
protein dependent pathway regulates five miRNAs, includ-
ing the miR-132/212 family in HEK293N cells stably 
transfected with AT1R and in primary cultures of cardiac 
fibroblasts, but not in cardiac myocytes.4 In this study, we 
identified multiple miR-132/212 targets involved in AngII, 
Endothelin-1 and canonical signalling pathways and sug-
gest that the miR-132/212 family functions to fine-tune the 
AngII actions in cardiac fibroblasts.
Several signalling pathways activated by AngII contrib-
ute to cardiac fibroblast stress, expansion of cell volume and 
contribute to hypertension in vivo. Interestingly, many of the 
regulated targets we identified belong in these or similar 
pathways. Of interest, we found target genes involved in 
Ca2+ binding (ANXA4 and CALU),21,22 proliferation and 
apoptosis (BTG2 and DYRK2),23,24 endothelial to mesenchy-
mal transition (MAP3K3 and ZFYVE16, also known as 
SARA),25,26 involved in cell cycle (CDKN1A, MAP3K3, 
NRAS, KRAS, PKC, VCAM, cJUN and RASA1)27 as well as 
in AngII signalling leading to hypertrophy and fibrosis 
(AGTR1, AC, PKC, EGR1, JAK2, cJUN and SOD2).28-31
All genes identified as targets, except PTEN and GRB2, 
were attenuated in fibroblasts overexpressing miR-
132/212. The increase in GRB2 might be explained by the 
missing miR-132/212 binding site and the fact that this 
molecule is activated by AT2R and subsequent Gi subunit 
activation30,31 and not activated by the Gq subunit account-
ing for most of the hypertrophic and hypertensive effects 
of AngII. The majority of targets were found to be attenu-
ated borderline significantly (0.05 < p <0.2; Table 1) and 
two genes, DYRK2 and MAP3K3, were significantly 
downregulated. These results support the notion that miR-
NAs typically exert modest inhibitory effects on many 
mRNAs, which often encode proteins that govern the same 
biological process or gene-regulatory networks.32
Interestingly, an evaluation of the biological effect of 
overexpressing miR-132/212 revealed that the fibroblast 
cell volume was significantly increased (p < 0.01), sug-
gesting that overexpression of the miRNAs mimic the 
AngII-mediated effects. Of note, multiple factors such as 
serum, starvation, density and plating conditions may 
influence cell proliferation and cell size,4 thus the biologi-
cal relevance of the phenotypic changes observed in AngII 
stimulated fibroblasts may be under the influence of other 
factors.
Several studies identify miR-132/212 involvement in 
the central nervous system, i.e. in neuronal function and 
plasticity. From these studies, it is widely acknowledged 
that miR-132/212 targets a wide panel of genes including 
RASA1.9,10,33 MiR-132/212 has been shown to be involved 
in neovascularisation, targeting the endothelial RASA1.34 
In one study, miR-132 was reported to be constitutively 
expressed and released by pericyte progenitor cells, and 
transplantation of these cells into mice with myocardial 
infarction showed an improvement in cardiac function 
through proangiogenic and antifibrotic activities via inhi-
bition of its targets RASA1 and Methyl-CpG binding pro-
tein 2 (MeCP2).35 Moreover a recent study showed that 
AngII induced expression of miR-132 targets PTEN and 
RASA1 in vascular smooth muscle cells.20 These targets 
were identified from prediction algorithms, and in vivo 
verification of the results was inconclusive.
It should be mentioned that in addition to miR-132 and 
miR-212, other miRNAs may also be involved in AngII-
mediated hypertension, and likewise at the levels of mRNA 
targets our studies have most likely not identified all impli-
cated mediators of the effect from miR-132 and miR-212 
in AngII signalling. Also, we cannot exclude that other fac-
tors such as Endothelin-1 and TGF-β, which work syner-
gistically to AngII, may influence the data presented 
herein. Another note of caution: transfection with pre-
miR-132/212 led to expression levels several magnitudes 
higher than those elicited by AngII treatment, which may 
obscure comparability of the cellular effects and increase 
the risk of off-targets effects.
In addition to the described concept of miR-132/212 
fine-tuning AngII actions in cardiac fibroblasts, it could be 
speculated that AngII signalling could be affected by 
miRNA redundancy. Thus, several miRNAs could coop-
eratively target various components of the signalling net-
work or be required to sufficiently repress a single target. 
In addition, some miRNAs seem to ‘balance’ specific 
pathways by targeting both positive and negative regula-
tory components. We are just beginning to understand 
these modes of action that uphold cellular homeostasis, 
allowing buffering against minor physiological variations.
Genetic deletions of miRNAs in many different 
organisms have shown that few developmental processes 
are absolutely dependent on single miRNAs.36,37 Clearly, 
miRNA biology represents a complex mode of gene 
regulation.
In summary, miR-132/212 mimic and analysis of geno-
typic read-outs identified approximately 600 mRNAs, 
including 22 validated targets involved in AngII signalling. 
The targets were found to be attenuated and only a few sig-
nificantly by miR-132/212 overexpression, supporting the 
notion of miR-132/212 conducting fine-tuning of AngII 
actions in cardiac fibroblasts.
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